Risk of Coronary Artery Disease Associated With Polymorphism of the Cytochrome P450 Epoxygenase CYP2J2
Martin Spiecker(Roche (Switzerland)), James K. Liao(Brigham and Women's Hospital), Darryl C. Zeldin(National Institute of Environmental Health Sciences), Andreas Mügge(Roche (Switzerland)), Koichi Node(Saga University), Klaus Lindpaintner(Roche (Switzerland)), Anika Huesing(Roche (Switzerland)), Jan Börgel(Roche (Switzerland)), Bernhard Maisch, Muhidien Soufi(Roche (Switzerland)), Alexander Sattler(Roche (Switzerland)), Thomas Hankeln(Johannes Gutenberg University Mainz), Jürgen R. Schaefer(Roche (Switzerland)), Harald Darius(Roche (Switzerland))
Cited by 241
Related Papers
Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies
|Circulation|1996|3.5k
Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
|European Heart Journal|2013|3.4k
Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines.
|Journal of Clinical Investigation|1995|1.8k